Status:
COMPLETED
Soy Isoflavones and Breast Cancer Risk Reduction
Lead Sponsor:
The University of Texas Medical Branch, Galveston
Collaborating Sponsors:
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
Conditions:
Breast Cancer
Eligibility:
FEMALE
30-42 years
Phase:
PHASE2
Brief Summary
Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are c...
Detailed Description
This is a randomized, double-blind study, with two arms and 100 women in each arm. Premenopausal women will be recruited and randomly allocated to take one of the two different dietary supplements in ...
Eligibility Criteria
Inclusion
- healthy premenopausal women
- 30 to 42 years old
- normal mammograms
- regular menstrual cycles
Exclusion
- abnormal mammograms
- first degree relatives with breast cancer
- pregnant or lactating
- peri- or post-menopause
- breast augmentation, reduction or lifting
- on oral contraceptive medications or exogenous hormones
- medically prescribed diets
- allergic reaction to soy products
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT00204490
Start Date
April 1 2004
End Date
May 31 2023
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Clinical Reserach Center, The University of Texas Medical Branch
Galveston, Texas, United States, 77555-0264